International Murex launching HIV RT drug resistance test in Europe by end of January.
This article was originally published in The Gray Sheet
Executive Summary
INTERNATIONAL MUREX LAUNCHING HIV RT DRUG RESISTANCE ASSAY IN EUROPE "at the end of this month," acting President and CEO Robert Cusick said Jan. 21 at a meeting with the New York Society of Security Analysts. The test is intended to detect HIV strains resistant to reverse transcriptase inhibitor therapies. Murex plans to introduce the test in the U.S. later this year for investigational use only.